|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1999-6-16
|
|
pubmed:abstractText |
We have previously demonstrated that intratumoral injection with Ad vectors expressing IL-2 or IL-12 can induce regression in a murine breast cancer model. These IL-2- or IL-12-induced antitumor responses were mainly mediated by Ag-specific T cells. Lymphotactin is a novel lymphocyte chemokine that can cause local accumulation of CD4+, CD8+, and NK cells. We hypothesized that addition of lymphotactin may enhance the antitumor immune responses induced by locally produced IL-2 and IL-12 as we have previously shown. To this end we constructed two double-recombinant adenoviral vectors expressing lymphotactin along with either IL-2 (Ad5 Lym/IL-2) or IL-12 (Ad5 Lym/IL-12). Subcutaneous injection of polyoma middle T (PyMT) or Neu (8142) transgenically derived breast adenocarcinoma cells, in the hind flank of FVB/n mice, results in the formation of tumor nodules in 14-21 days. We show that these constructs elicit potent antitumor responses when administered intratumorally. The antitumor responses are long lasting as determined by rechallenge experiments and hence demonstrate a protective immunity. These observations indicate that by augmenting the antitumor response with adenoviral vectors expressing lymphotactin in combination with IL-2 or IL-12 is a novel way to enhance immunotherapeutic approaches.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, C,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines,
http://linkedlifedata.com/resource/pubmed/chemical/Sialoglycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Xcl1 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/lymphotactin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1043-0342
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
697-709
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:10210138-Adenoviridae,
pubmed-meshheading:10210138-Animals,
pubmed-meshheading:10210138-Antigens, CD3,
pubmed-meshheading:10210138-CD4-Positive T-Lymphocytes,
pubmed-meshheading:10210138-CD8-Positive T-Lymphocytes,
pubmed-meshheading:10210138-Cell Line,
pubmed-meshheading:10210138-Chemokines, C,
pubmed-meshheading:10210138-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:10210138-Drug Therapy, Combination,
pubmed-meshheading:10210138-Gene Therapy,
pubmed-meshheading:10210138-Genetic Vectors,
pubmed-meshheading:10210138-Immunohistochemistry,
pubmed-meshheading:10210138-Interferon-gamma,
pubmed-meshheading:10210138-Interleukin-12,
pubmed-meshheading:10210138-Interleukin-2,
pubmed-meshheading:10210138-Interleukin-4,
pubmed-meshheading:10210138-Lymphokines,
pubmed-meshheading:10210138-Mammary Neoplasms, Experimental,
pubmed-meshheading:10210138-Mice,
pubmed-meshheading:10210138-Mice, Transgenic,
pubmed-meshheading:10210138-Models, Genetic,
pubmed-meshheading:10210138-Sialoglycoproteins,
pubmed-meshheading:10210138-Time Factors
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models.
|
|
pubmed:affiliation |
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
